CN102526410A - Medicinal composition for treating functional constipation - Google Patents
Medicinal composition for treating functional constipation Download PDFInfo
- Publication number
- CN102526410A CN102526410A CN2012100409828A CN201210040982A CN102526410A CN 102526410 A CN102526410 A CN 102526410A CN 2012100409828 A CN2012100409828 A CN 2012100409828A CN 201210040982 A CN201210040982 A CN 201210040982A CN 102526410 A CN102526410 A CN 102526410A
- Authority
- CN
- China
- Prior art keywords
- parts
- constipation
- radix
- functional constipation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 241000005787 Cistanche Species 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 2
- 241000202755 Areca Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 244000080767 Areca catechu Species 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 241000218378 Magnolia Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000000843 powder Substances 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 230000013872 defecation Effects 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 239000004375 Dextrin Substances 0.000 description 12
- 229920001353 Dextrin Polymers 0.000 description 12
- 235000019425 dextrin Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 11
- 210000003608 fece Anatomy 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 239000012567 medical material Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 210000001809 melena Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002475 laxative effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000008141 laxative Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241001673966 Magnolia officinalis Species 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000008144 emollient laxative Substances 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000013546 non-drug therapy Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 206010010539 Congenital megacolon Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010056325 Faecaloma Diseases 0.000 description 1
- 208000008415 Fecal Impaction Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000004592 Hirschsprung disease Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 238000003457 Shi epoxidation reaction Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- 125000002099 lactulose group Chemical group 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000022560 parathyroid gland disease Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Abstract
The invention discloses a medicinal composition for treating functional constipation and relates to the technical field of Chinese medicines. The medicinal composition is prepared from the following Chinese herbal medicines in part by weight: 6 to 10 parts of officinal magnolia mark, 8 to 12 parts of areca seed, 6 to 10 parts of liquoric root, 10 to 15 parts of baical skullcap root, 12 to 16 parts of Chinese angelica, 8 to 12 parts of desertliving cistanche, 18 to 25 parts of prepared rehmannia root and 18 to 25 parts of prepared largehead atractylodes rhizome. The medicinal composition for treating the functional constipation has the advantages of good curative effect and high safety.
Description
Technical field
The present invention relates to the Chinese medicine technical field, particularly relate to a kind of pharmaceutical composition that is used to treat functional constipation.
?
Background technology
Chronic constipation is a kind of common symptom, and its cause of disease is complicated, brings many worries to the patient, has a strong impact on patient's quality of life.Along with social development, survival pressure increases, dog-eat-dog, and the change of living habit such as dietary structure, and the incidence rate of constipation becomes ascendant trend.
Relevant in the world functional gastrointestinal disorder comprised constipation, was releasing Rome I standard aspect diagnosis, pathophysiology and the treatment in 1994, released Rome II standard in 2000.Notion to constipation is the universal standard with Rome II standard in the world.Be that constipation is meant that feces is dry and hard, difficult defecation or defecation is felt not to the utmost and defecation frequency reduces.
Chronic constipation can be divided into organic constipation and functional constipation on the etiology.Organic constipation mainly is because the constipation of organic diseases because of causing; The organic diseases of chronic constipation is because of mainly containing gastroenteropathy (intestinal canal tumour, congenital megacolon etc.), perianal (proctoptosis, encysted rectum), nervous system disease (multiple sclerosis, parkinson disease, apoplexy, spinal cord injury and peripheral neuropathy), endocrine or metabolic disease (diabetes enteropathy, hypothyroidism, disease of parathyroid glands) and psychosis, the constipation of also answering eliminant physical property factor (opioid drug, anticholinergic agent, antidepressants, calcium-channel antagonists, antacid, chalybeate, diarrhea medicine, diuretic, antihistaminic etc.) to cause simultaneously.
Functional constipation be get rid of organic diseases because of and the constipation that causes of other factors, and meet following standard: in 12 middle of the month in the past, continue or accumulation has following two or more symptoms at least 12 weeks: (1) 1/4 time defecation is required great effort; (2) 1/4 time feces are to be lumps or hard; (3) feel not to the utmost greater than 1/4 time defecation; (4) sense of obstruction is arranged or discharge difficulty greater than 1/4 time anus; (5) need during defecation to assist (flesh hinders at the bottom of supporting basin) greater than 1/4 time with thing; (6) weekly defecation less than 3 times.According to difficult defecation happening part and dyskinesis, functional constipation generally is divided into three types: chronic slow-transit constipation (STC), outlet obstructed type constipation (OOC) and mixed type constipation (MIX).STC is the common type of functional constipation, accounts for 40%, and OOC is then mostly occurring child, women and old people.STC is relevant with the colon dyskinesia, and the digestive tract power disease is newly divided apoplexy due to endogenous wind in Bangkok, and clear and definite enteric nervous is sick, myenteron is sick, parkinson disease, endocrinopathy or spinal cord injury etc. can cause the colon transmission delay, becomes STC.Chronic slow-transit constipation patient intestinal Cajal Interstitial cell (ICC) quantity reduces, volume-diminished, so can think that it is the cytological main feature of chronic slow-transit constipation intestinal tissue that ICC reduces.C-kit is a kind of proto-oncogene, is positioned on No. 5 chromosome w sites, and its coding kit receptor, the latter belongs to the EGFR-TK membrane receptor.Express at ICC and all to express c-kit, and ICC can cross the kit receptor and accept various signals, if block the kit receptor; Not only ICC grows and is affected; And its function also will lose, so that ICC has or not c-kit to express with intestinal power is closely related, therefore can utilize c-kit antibody labeling identification ICC.OOC is then relevant unusually to defecation reflex sense threshold value with anal sphincter orthofunction or rectum, and the normal main suit of patient defecation effort, anus bearing down, defecation are felt not to the utmost, feces volume is few, quality is hard or the shaping soft stool.The mixed type constipation is to possess above-mentioned two characteristics.Because all kinds constipation pathogenesis is different, so should pay attention to self the impression characteristic to constipation, tentatively carry out typing with the labor patient, take the corresponding treatment measure.
Diseased region that functional constipation is special and pathogenesis make very difficulty of clinical treatment, and constipation therapy medicine curative effect at present commonly used is undesirable: or treatment time is long, or invalid, or discharges a small amount of loose stool, or erious adverse reaction so that patient are difficult to accept.Adopt non-drug therapy and Drug therapy at present clinically, severe patient even need carry out surgical operation therapy.
Adopt non-drug therapy, like the change of living habit such as the guidance of defecation mode, diet and biofeedback therapy etc., mostly need pass through the long time can alleviate, a lot of patients are difficult to persevere because of individual factor.
The main medicine of treatment constipation has irritant laxative, emollient laxative, osmotic laxative and permeability laxative and motivator medicine etc.The irritant laxative effect is strong and rapid; Be used for fecal impaction more and need rapid relieving constipation patient, unsuitable prolonged application is because of it stimulates intestinal mucosa and intestinal wall plexus nervorum; Improve the mucosa permeability; Influenced enteral water, electrolyte and vitamin and absorbed, also can cause the large intestine myasthenia, formed medication dependency and fecal incontinence down to disorderly; Osmotic laxative can increase the capacity of stool, but can not increase colon tension force effectively, and the slow person of intestinal movement uses limited; The emollient laxative mouthfeel is poor, and a little less than the effect, long-time use can cause untoward reaction such as fatsoluble vitamin malabsorption, crissum oil seepage; The permeability laxative is lactulose for example, in small intestinal, does not absorb, and they decompose through colon bacteria and discharge organic acid and in colonic generation effect, has abdominal distention or stomachache and prolonged application weak curative effect and is prone to cause shortcoming such as intestinal microbial population change; And the intestinal motive force medicine usually need be united the other drug use, and side effect is also bigger.
Summary of the invention
In view of the deficiency of prior art, the objective of the invention is to through a large amount of animal experiment studies, a kind of pharmaceutical composition of more safe and reliable treatment functional constipation is provided.
The objective of the invention is to realize like this:
A kind of pharmaceutical composition of treating functional constipation is prepared from the active component of following weight portion: Cortex Magnoliae Officinalis 6-10 part, Semen Arecae 8-12 part, Radix Glycyrrhizae 6-10 part, Radix Scutellariae 10-15 part, Radix Angelicae Sinensis 12-16 part, Herba Cistanches 8-12 part, Radix Rehmanniae Preparata 18-25 part, Rhizoma Atractylodis Macrocephalae (parched) 18-25 part.
Preferably, the pharmaceutical composition of described treatment functional constipation is prepared from the active component of following weight portion: 8 parts of Cortex Magnoliae Officinalis, 10 parts of Semen Arecaes, 8 parts in Radix Glycyrrhizae, 12 parts of Radix Scutellariaes, 15 parts of Radix Angelicae Sinensis, 10 parts of Herba Cistanches, 20 parts of Radix Rehmanniae Preparata, 20 parts of Rhizoma Atractylodis Macrocephalae (parched)s.
Further preferably, the pharmaceutical composition of described treatment functional constipation is an oral formulations.
Again further preferably, the pharmaceutical composition of described treatment functional constipation is a granule.
Discover that through animal experiment the pharmaceutical composition of being made up of above-mentioned active component has significant curative effect aspect the treatment functional constipation rat model.Therefore, second purpose of the present invention is to provide a kind of new medical use, the application of promptly above-mentioned Chinese medicine composition in the medicine of preparation treatment functional constipation.
According to the record of Chinese medicine historical data, above-mentioned 8 flavor Chinese medicines have following pharmacologically active and function cures mainly:
Cortex Magnoliae Officinalis: main warming middle-JIAO, QI invigorating, the expectorant therapeutic method to keep the adverse QI flowing downwards is controlled cholera and stomachache, distension, cold in the stomach is contrary, and vomiting is more than in the heart, lets out dysentery, drenches to reveal, and removes and shies, and going or staying heat is ended stuffy sensation with restlessness, thick the intestines and stomach.Select dry dried bark, root bark and the branch skin of Magnoliacea plant Cortex Magnoliae Officinalis Magnolia officinalis Rehd. et Wils. or magnolia officinalis rehd.et wils.var.biloba rehd.et wils. Magnolia officinalis Rehd. et Wils. var. biloba Rehd. et Wils. for use.
Semen Arecae: anthelmintic; Removing food stagnancy; The therapeutic method to keep the adverse QI flowing downwards; Row water; Preventing the attack (or recurrence) of malaria.Malnutrition due to parasitic infestation; Dyspepsia; Abdominal distention; Heavy behind the dysentery; Foot gas; Edema; Malaria.Select the seed of babassu Semen Arecae Areca catechu Linn. for use.
Radix Glycyrrhizae: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.Be used for weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious pain of extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.Select Fisch. for use, Glycyrrhiza inflata Bat. G. inflata Bat., or the root and rhizome of Glycyrrhiza glabra L. G. glabra L. for dicotyledon pulse family Leguminosae Radix Glycyrrhizae Glycyrrhiza uralensis.
Radix Scutellariae: heat clearing and damp drying, eliminating fire and detoxication, hemostasis, antiabortive, blood pressure lowering.Be used for hygropyrexia, fever disease in summer vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness, dysentery, jaundice, the cough due to lung-heat, the hyperpyrexia excessive thirst, heat in blood is told nosebleed, carbuncle sore tumefacting virus, frequent fetal movement.Select the dry root of labiate Radix Scutellariae Scutellaria baicalensis Georgi for use.
Radix Angelicae Sinensis: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.Be used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.Select the dry root of umbelliferae angelica Angelica sinensis (Oliv.) Diels for use.
Herba Cistanches: kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation.Be used for sexual impotence, infertile, soreness of the waist and knees, muscles and bones is unable, the dryness of the intestine constipation.Be selected from the chylocaulous of the dry zone scale leaf of orobanchaceae plant cistanche Cistanche deserticola Y.C. Ma.
Radix Rehmanniae Preparata: it is moist to enrich blood; The benefit essence is filled out marrow.Be used for blood deficiency and yellow complexion; Dizzy cardiopalmus; Menoxenia; Collapse more than; Hepatic and renal YIN deficiency; Hectic fever night sweat; The seminal emission sexual impotence; Infertility; Menoxenia; Metrostaxis; Soreness of the waist and knees; Hiccough and deaf; The head is dim-sighted; Early whitening of beard and hair; Quench one's thirst; Constipation; The dyspnea with rapid and short breath of suffering from a deficiency of the kidney.Be selected from the tuber of scrophulariaceae rehmannia glutinosa plant (Rehmannia glutinosa (Gdertn) Iibosch.ex Fisch. et Mey.).
The Rhizoma Atractylodis Macrocephalae: invigorating the spleen and benefiting QI, the dampness diuretic, hidroschesis, antiabortive.Be used for insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.Select the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz. for use.
Above-mentioned each Chinese crude drug is prepared into the method for preparing of compound preparation of the present invention, comprises the steps:
The first step, preparation clear paste powder:
1) get the raw materials ready: take by weighing the above-mentioned Chinese crude drug that cleans up by recipe quantity, subsequent use;
2) decoct: decocte with water, first fries in shallow oil every jar, and to add water be 8 times of medical material total amount, kept 3 hours behind the ebuillition of heated, extracting solution filters through 200 order filters and gets into settling tank; Second fries in shallow oil the water heating extraction that adds 4 times of medical material amounts, protects and boils 3 hours, and extracting solution filters through 200 order filters and gets into settling tank;
3) deposition: the extracting solution deposition is 24～36 hours in the settling tank, extracts supernatant and is filtered in the triple effect evaporator through 200 order filters, and precipitate is by offal treatment;
4) concentrate: when supernatant is concentrated into relative density and is 1.00～1.10 (40 ℃ of mensuration) in triple effect evaporator; Rare clear paste is filtered in the suction vacuum decompressioning and concentrating tank through 200 order filters; Concentrate and be mixed to and go out cream when relative density is 1.30～1.32 (90 ℃ of mensuration); To storing in the cream bucket, subsequent use;
5) drying: vacuum :-0.1MPa wherein, temperature: 78～82 ℃, 20～24 hours drying times;
6) beat powder: smashing fineness 80 mesh sieves obtain the clear paste powder;
In second step, according to the clear paste powder: dextrin: 55% ethanol is that the weight ratio of 1:1～3:0.1～0.3 takes by weighing clear paste powder, dextrin and 55% ethanol, and wherein 55% ethanol is meant that volumetric concentration is 55% ethanol water;
The 3rd step, clear paste powder and dextrin are dropped in the trough type mixing machine, stirred 20 minutes, slowly add 55% ethanol while stirring, to processing soft material, with the granulation of 12 order stainless steel sifts, 65～75 ℃ of dryings 2 hours, taking-up cools and promptly gets described granule.
Compared with prior art, the present invention has following advantage and progressive significantly: (1) good effect.Compare with the model group mice, Chinese medicine of the present invention is low, the average daily feces volume of high dose group mice, first grain melena efflux time all have significant difference (
P＜0.05 or
P＜0.01), this shows that Chinese medicine composition of the present invention can obviously improve the mice feces volume, strengthens the mouse intestinal propulsive force, alleviates the symptom of slow-remove type mice constipation.(2) safe.Because medicine of the present invention is adopting the Chinese medicine material to be prepared from, toxicity is low, and patient's medication is safer.
The specific embodiment
Further specify the present invention through embodiment below.Embodiments of the invention are only used for explaining the present invention, rather than limitation of the present invention, under design prerequisite of the present invention, the simple modifications of method for preparing of the present invention are all belonged to the present invention and require the scope protected.
The preparation of embodiment 1 Chinese medicine oral liquid
Crude drug prescription: 8 parts of Cortex Magnoliae Officinalis, 10 parts of Semen Arecaes, 8 parts in Radix Glycyrrhizae, 12 parts of Radix Scutellariaes, 15 parts of Radix Angelicae Sinensis, 10 parts of Herba Cistanches, 20 parts of Radix Rehmanniae Preparata, 20 parts of Rhizoma Atractylodis Macrocephalae (parched)s.
Method for preparing:
The first step, preparation clear paste powder:
1) get the raw materials ready: take by weighing the above-mentioned Chinese crude drug that cleans up by recipe quantity, subsequent use;
2) decoct: decocte with water, first fries in shallow oil every jar, and to add water be 8 times of medical material total amount, kept 3 hours behind the ebuillition of heated, extracting solution filters through 200 order filters and gets into settling tank; Second fries in shallow oil the water heating extraction that adds 4 times of medical material amounts, protects and boils 3 hours, and extracting solution filters through 200 order filters and gets into settling tank;
3) deposition: the extracting solution deposition is 24 hours in the settling tank, extracts supernatant and is filtered in the triple effect evaporator through 200 order filters, and precipitate is by offal treatment;
4) concentrate: when supernatant is concentrated into relative density and is 1.10 (40 ℃ of mensuration) in triple effect evaporator; Rare clear paste is filtered in the suction vacuum decompressioning and concentrating tank through 200 order filters; Concentrate and be mixed to and go out cream when relative density is 1.30～1.32 (90 ℃ of mensuration); To storing in the cream bucket, subsequent use;
5) drying: vacuum :-0.1MPa wherein, temperature: 78～82 ℃, 20 hours drying times;
6) beat powder: smashing fineness 80 mesh sieves obtain the clear paste powder;
In second step, according to the clear paste powder: dextrin: 55% ethanol is that the weight ratio of 1:2:0.2 takes by weighing clear paste powder, dextrin and 55% ethanol, and wherein 55% ethanol is meant that volumetric concentration is 55% ethanol water;
The 3rd step, clear paste powder and dextrin are dropped in the trough type mixing machine, stirred 20 minutes, slowly add 55% ethanol while stirring, to processing soft material, with the granulation of 12 order stainless steel sifts, 70 ℃ of dryings 2 hours, taking-up cools and promptly gets described granule.
The preparation of embodiment 2 Chinese medicine oral liquid
Crude drug prescription: 6 parts of Cortex Magnoliae Officinalis, 12 parts of Semen Arecaes, 8 parts in Radix Glycyrrhizae, 15 parts of Radix Scutellariaes, 12 parts of Radix Angelicae Sinensis, 8 parts of Herba Cistanches, 25 parts of Radix Rehmanniae Preparata, 18 parts of Rhizoma Atractylodis Macrocephalae (parched)s.
Method for preparing:
The first step, preparation clear paste powder:
1) get the raw materials ready: take by weighing the above-mentioned Chinese crude drug that cleans up by recipe quantity, subsequent use;
2) decoct: decocte with water, first fries in shallow oil every jar, and to add water be 8 times of medical material total amount, kept 3 hours behind the ebuillition of heated, extracting solution filters through 200 order filters and gets into settling tank; Second fries in shallow oil the water heating extraction that adds 4 times of medical material amounts, protects and boils 3 hours, and extracting solution filters through 200 order filters and gets into settling tank;
3) deposition: the extracting solution deposition is 30 hours in the settling tank, extracts supernatant and is filtered in the triple effect evaporator through 200 order filters, and precipitate is by offal treatment;
4) concentrate: when supernatant is concentrated into relative density and is 1.05 (40 ℃ of mensuration) in triple effect evaporator; Rare clear paste is filtered in the suction vacuum decompressioning and concentrating tank through 200 order filters; Concentrate and be mixed to and go out cream when relative density is 1.30～1.32 (90 ℃ of mensuration); To storing in the cream bucket, subsequent use;
5) drying: vacuum :-0.1MPa wherein, temperature: 78～82 ℃, 24 hours drying times;
6) beat powder: smashing fineness 80 mesh sieves obtain the clear paste powder;
In second step, according to the clear paste powder: dextrin: 55% ethanol is that the weight ratio of 1:3:0.3 takes by weighing clear paste powder, dextrin and 55% ethanol, and wherein 55% ethanol is meant that volumetric concentration is 55% ethanol water;
The 3rd step, clear paste powder and dextrin are dropped in the trough type mixing machine, stirred 20 minutes, slowly add 55% ethanol while stirring, to processing soft material, with the granulation of 12 order stainless steel sifts, 75 ℃ of dryings 2 hours, taking-up cools and promptly gets described granule.
The preparation of embodiment 3 Chinese medicine oral liquid
Crude drug prescription: 10 parts of Cortex Magnoliae Officinalis, 10 parts of Semen Arecaes, 10 parts in Radix Glycyrrhizae, 10 parts of Radix Scutellariaes, 15 parts of Radix Angelicae Sinensis, 12 parts of Herba Cistanches, 25 parts of Radix Rehmanniae Preparata, 25 parts of Rhizoma Atractylodis Macrocephalae (parched)s.
Method for preparing:
The first step, preparation clear paste powder:
1) get the raw materials ready: take by weighing the above-mentioned Chinese crude drug that cleans up by recipe quantity, subsequent use;
2) decoct: decocte with water, first fries in shallow oil every jar, and to add water be 8 times of medical material total amount, kept 3 hours behind the ebuillition of heated, extracting solution filters through 200 order filters and gets into settling tank; Second fries in shallow oil the water heating extraction that adds 4 times of medical material amounts, protects and boils 3 hours, and extracting solution filters through 200 order filters and gets into settling tank;
3) deposition: the extracting solution deposition is 36 hours in the settling tank, extracts supernatant and is filtered in the triple effect evaporator through 200 order filters, and precipitate is by offal treatment;
4) concentrate: when supernatant is concentrated into relative density and is 1.10 (40 ℃ of mensuration) in triple effect evaporator; Rare clear paste is filtered in the suction vacuum decompressioning and concentrating tank through 200 order filters; Concentrate and be mixed to and go out cream when relative density is 1.30～1.32 (90 ℃ of mensuration); To storing in the cream bucket, subsequent use;
5) drying: vacuum :-0.1MPa wherein, temperature: 78～82 ℃, 24 hours drying times;
6) beat powder: smashing fineness 80 mesh sieves obtain the clear paste powder;
In second step, according to the clear paste powder: dextrin: 55% ethanol is that the weight ratio of 1:2:0.3 takes by weighing clear paste powder, dextrin and 55% ethanol, and wherein 55% ethanol is meant that volumetric concentration is 55% ethanol water;
The 3rd step, clear paste powder and dextrin are dropped in the trough type mixing machine, stirred 20 minutes, slowly add 55% ethanol while stirring, to processing soft material, with the granulation of 12 order stainless steel sifts, 75 ℃ of dryings 2 hours, taking-up cools and promptly gets described granule.
Embodiment 4 medicines of the present invention are to the influence of functional constipation rat model
60 of specific-pathogen free SPF level ICR Mus, male and female half and half, body weight 20～25 grams are divided into 4 groups: normal control group, model control group, Chinese medicine low dose group and Chinese medicine high dose group, 15 every group at random.All mices are inserted respectively in the mice metabolic cage, and SPF level environment is raised.Adaptability was fed after 3 days, Chinese drug-treated group and model control group mouse subcutaneous injection morphine hydrochloride 2.5mg/ (kgd), normal control group injection equivalent normal saline.A mice stool of per 3 days records grain number, stool dry weight and mice body weight are calculated the average daily defecation weight of mice (g).Reduce with the average daily feces volume of mice, and average daily feces volume compares with the normal control group and have significant difference as the successful sign of the foundation of chronic slow-transit constipation mouse model, stop drug administration by injection after the modeling successfully.
Give with the mice of modeling success back (raise and rose in the 46th day) according to like following table 1 dosage regimen administration:
Table 1. laboratory animal is divided into groups and administration
| Divide into groups | Sample size (only) | Dosage |
| Normal group | 15 | Distilled water with volume |
| Model group | 15 | Distilled water with volume |
| The Chinese medicine low dose group | 15 | 20g·kg -1·d -1Clear paste powder (embodiment 1 preparation) |
| The Chinese medicine high dose group | 15 | 40g·kg -1·d -1Clear paste powder (embodiment 1 preparation) |
Be administered once every day, whenever at a distance from a mice stool of 1 day record grain number, stool dry weight and mice body weight, calculates the average daily defecation weight of mice (g).Average daily feces volume of mice and compared with normal reduce, and show that the chronic slow-transit constipation degree increases.
Measure first grain melena efflux time with the active carbon administration by gavage.All mice fasting in 1 week of drug withdrawal 24 hours, per os pours into 100mg/ml carbon suspensioning liquid 2ml.Irritate stomach timing when finishing beginning from active carbon, record is from irritating stomach to time that first grain melena is discharged.The longer chronic slow-transit constipation degree that shows of first grain melena efflux time is big more.
Experimental data typing SPSS211.0 statistical package, statistical method is selected for use
tCheck, p<0.05 for difference has the significance meaning.
Experimental result shows:
(1) and compared with normal, the average daily feces volume of model group mice, first grain melena efflux time all have extremely significant difference (p < 0.01), show that the chronic slow-transit constipation mouse model builds successfully;
(2) compare with the model group mice, Chinese medicine of the present invention is low, the average daily feces volume of high dose group mice, first grain melena efflux time all have significant difference (
P＜0.05 or
P＜0.01), this shows that Chinese medicine composition of the present invention can obviously improve the mice feces volume, strengthens the mouse intestinal propulsive force, alleviates the symptom of slow-remove type mice constipation.
Table 2. Chinese medicine composition is to the influence of chronic slow-transit constipation mice
| Group | Stool weight (g/d) | Melena efflux time (min) |
| The normal control group | 10.86±3.02 | 156±49 |
| Model control group | ?4.13±1.78 ￥￥ | ? 375±76 ￥￥ |
| The Chinese medicine low dose group | ?6.95±2.10 ￥* | ?213±83 ** |
| The Chinese medicine high dose group | 7.76±2.61 ** | 220±57 ** |
Compare with the normal control group,
$ P＜0.05,
$$ P＜0.01;
Compare * with model control group
P＜0.05, * *
P＜0.01.
Claims (4)
1. pharmaceutical composition of treating functional constipation, it is characterized in that: the active component following weight portion is prepared from: Cortex Magnoliae Officinalis 6-10 part, Semen Arecae 8-12 part, Radix Glycyrrhizae 6-10 part, Radix Scutellariae 10-15 part, Radix Angelicae Sinensis 12-16 part, Herba Cistanches 8-12 part, Radix Rehmanniae Preparata 18-25 part, Rhizoma Atractylodis Macrocephalae (parched) 18-25 part.
2. a kind of pharmaceutical composition of treating functional constipation according to claim 1, it is characterized in that: the active component following weight portion is prepared from: 8 parts of Cortex Magnoliae Officinalis, 10 parts of Semen Arecaes, 8 parts in Radix Glycyrrhizae, 12 parts of Radix Scutellariaes, 15 parts of Radix Angelicae Sinensis, 10 parts of Herba Cistanches, 20 parts of Radix Rehmanniae Preparata, 20 parts of Rhizoma Atractylodis Macrocephalae (parched)s.
3. a kind of pharmaceutical composition of treating functional constipation according to claim 1 and 2 is characterized in that: said pharmaceutical composition is an oral formulations.
4. a kind of pharmaceutical composition of treating functional constipation according to claim 3 is characterized in that: said drug composition oral preparation is a granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210040982 CN102526410B (en) | 2012-02-23 | 2012-02-23 | Medicinal composition for treating functional constipation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210040982 CN102526410B (en) | 2012-02-23 | 2012-02-23 | Medicinal composition for treating functional constipation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526410A true CN102526410A (en) | 2012-07-04 |
| CN102526410B CN102526410B (en) | 2013-04-24 |
Family
ID=46335230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210040982 Expired - Fee Related CN102526410B (en) | 2012-02-23 | 2012-02-23 | Medicinal composition for treating functional constipation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526410B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104257962A (en) * | 2014-09-09 | 2015-01-07 | 扬中牧乐药业有限公司 | Granule for preventing and treating sow constipation |
| CN105943988A (en) * | 2016-06-20 | 2016-09-21 | 凌贞梅 | Medicine for treating constipation and preparation method thereof |
| CN106039024A (en) * | 2016-07-26 | 2016-10-26 | 周慧 | Traditional Chinese medicine preparation for curing functional constipation |
| CN109260410A (en) * | 2018-03-12 | 2019-01-25 | 季旭明 | A kind of improvement functional consitipation food and medicine consangunity beverage and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518641A (en) * | 2008-02-28 | 2009-09-02 | 北京中泰天和科技有限公司 | Traditional Chinese preparation used for preventing and treating functional constipation |
| CN101623384A (en) * | 2008-07-08 | 2010-01-13 | 魏翠玲 | Chinese medicinal composition for treating constipation |
| KR20100064120A (en) * | 2008-12-04 | 2010-06-14 | 주식회사 엘지생활건강 | Constipation releaving health food composition containing aloe vera and aloe aborescens |
-
2012
- 2012-02-23 CN CN 201210040982 patent/CN102526410B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518641A (en) * | 2008-02-28 | 2009-09-02 | 北京中泰天和科技有限公司 | Traditional Chinese preparation used for preventing and treating functional constipation |
| CN101623384A (en) * | 2008-07-08 | 2010-01-13 | 魏翠玲 | Chinese medicinal composition for treating constipation |
| KR20100064120A (en) * | 2008-12-04 | 2010-06-14 | 주식회사 엘지생활건강 | Constipation releaving health food composition containing aloe vera and aloe aborescens |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104257962A (en) * | 2014-09-09 | 2015-01-07 | 扬中牧乐药业有限公司 | Granule for preventing and treating sow constipation |
| CN105943988A (en) * | 2016-06-20 | 2016-09-21 | 凌贞梅 | Medicine for treating constipation and preparation method thereof |
| CN106039024A (en) * | 2016-07-26 | 2016-10-26 | 周慧 | Traditional Chinese medicine preparation for curing functional constipation |
| CN109260410A (en) * | 2018-03-12 | 2019-01-25 | 季旭明 | A kind of improvement functional consitipation food and medicine consangunity beverage and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526410B (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN101822704B (en) | Drug combination for removing freckles and preparation method thereof | |
| CN102526410B (en) | Medicinal composition for treating functional constipation | |
| CN100409883C (en) | Chinese medicinal composition for treating agrypnia, functional gastricism and astriction and its preparation method | |
| CN106511864A (en) | Traditional Chinese medicine composition and preparation method and applications thereof in treatment of cervical carcinoma | |
| CN103610795B (en) | A kind of preparation method of eucommia bark depressor oral formulations | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN104740467A (en) | Traditional Chinese medicine preparation for treating functional uterine bleeding and production process of traditional Chinese medicine preparation | |
| CN101095886A (en) | Chinese traditional medicine for treating heart neurosis and method for preparing the same | |
| CN1331509C (en) | Chinese medicine for treating astriction and preparing method | |
| CN103656174A (en) | Old people intestine-moistening bowel-relaxing health-care product containing xylooligosaccharide | |
| CN103040997A (en) | Prokinetic traditional Chinese medicinal composition and preparation and application thereof | |
| CN103690869B (en) | Chinese medicine for the treatment of irritable bowel syndrome and preparation method thereof | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN100488526C (en) | Oral preparation | |
| CN102357175B (en) | Traditional Chinese medicine composite for regulating nervous system dysfunction and application thereof | |
| CN100558385C (en) | A kind of pharmaceutical composition for the treatment of irritable bowel syndrome, preparation and preparation method thereof | |
| CN101322788B (en) | Chinese medicine for treating vitiligo and preparation | |
| CN105920231A (en) | Traditional Chinese medicine preparation and capsule for treating constipation and preparation method of traditional Chinese medicine preparation and capsule | |
| CN106075180A (en) | A kind of Chinese medicine treating intravertebral anesthesia postoperative urine retention and preparation method thereof | |
| CN104547945A (en) | Traditional Chinese medicine preparation for treating scrofula and preparation method of traditional Chinese medicine preparation | |
| CN105521370A (en) | Pharmaceutical preparation for treating colon cancer and application thereof | |
| CN104288643A (en) | Pharmaceutical composition for treating consumptive disease nocturnal emission and preparation method thereof | |
| CN104208510A (en) | Medicine for treating chronic nephritis | |
| CN104116930A (en) | Traditional Chinese medicament for treating liver-kidney yin deficiency type meniere disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cheng Bo Inventor before: Cao Xiane |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CAO XIANE TO: CHENG BO |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUDONG XINYU TECHNOLOGY INNOVATION PARK CO., LTD. Free format text: FORMER OWNER: XU CONGYU Effective date: 20131105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131105 Address after: 226400 North Road, the Yellow River Road, Rudong Economic Development Zone, Rudong County, Jiangsu, Nantong Patentee after: Rudong Xinyu Technology Park Co. Ltd. Address before: 276017 A302 building, Linyi hi tech Industrial Development Zone, Shandong, China Patentee before: Xu Congyu |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20160223 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |